Skip to main content
Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging 4/2010

01.04.2010 | Original Article

Five months’ follow-up of patients with and without iodine-positive lymph node metastases of thyroid carcinoma as disclosed by 131I-SPECT/CT at the first radioablation

verfasst von: Daniela Schmidt, Rainer Linke, Michael Uder, Torsten Kuwert

Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging | Ausgabe 4/2010

Einloggen, um Zugang zu erhalten

Abstract

Purpose

In differentiated thyroid carcinoma (DTC), 131I-SPECT/CT is more accurate in identifying radioiodine-positive lymph node metastases (LNM) than planar whole-body scans (WBS). The purpose of this study was to investigate the value of 131I-SPECT/CT performed at the first radioablation to predict the occurrence and/or persistence of cervical radioiodine-positive LNM 5 months later.

Methods

The study included 81 DTC patients that had had SPECT/ spiral CT after radioablation of thyroid remnants after thyroidectomy. The patients were re-examined 5 months later using 131I-WBS performed at TSH stimulation. In addition, SPECT/CT of the neck was performed in patients with iodine-positive cervical foci to distinguish between thyroid remnant and LNM. The outcome variable of the study was the detection or exclusion of iodine-positive cervical LNM.

Results

Of 61 patients without a SPECT/CT diagnosis of 131I-positive LNM at radioablation, 60 had no 131I-positive LNM at follow-up. In the remaining patient of this group, a new radioiodine-positive LNM was detected. In 17 of 20 patients with a SPECT/CT diagnosis of 131I-positive LNM (n = 19) or an indeterminate lesion (n = 1) at first radioablation, no 131I-positive LNM were detected 5 months later. Radioiodine-positive LNM persisted in three patients of this group.

Conclusion

131I-SPECT/CT has a high negative predictive value with regard to the occurrence of radioiodine-positive cervical LNM 5 months after initial therapy. The majority of iodine-positive LNM diagnosed by SPECT/CT at radioablation disappear within 5 months. These findings motivate further research into the value of 131I-SPECT/CT of the neck for predicting recurrence and planning surgical reintervention in DTC.
Literatur
1.
Zurück zum Zitat Seidlin SM, Marinelli LD, Oshry E. Radioactive iodine therapy: effect on functioning metastases of adenocarcinoma of the thyroid. JAMA 1946;132:838–47. Seidlin SM, Marinelli LD, Oshry E. Radioactive iodine therapy: effect on functioning metastases of adenocarcinoma of the thyroid. JAMA 1946;132:838–47.
2.
Zurück zum Zitat Carlisle MR, Lu C, McDougall IR. The interpretation of 131I scans in the evaluation of thyroid cancer, with an emphasis on false positive findings. Nucl Med Commun 2003;24:715–35.CrossRefPubMed Carlisle MR, Lu C, McDougall IR. The interpretation of 131I scans in the evaluation of thyroid cancer, with an emphasis on false positive findings. Nucl Med Commun 2003;24:715–35.CrossRefPubMed
3.
Zurück zum Zitat Seo Y, Mari C, Hasegawa BH. Technological development and advances in single-photon emission computed tomography/computed tomography. Semin Nucl Med 2008;38:177–98.CrossRefPubMed Seo Y, Mari C, Hasegawa BH. Technological development and advances in single-photon emission computed tomography/computed tomography. Semin Nucl Med 2008;38:177–98.CrossRefPubMed
4.
Zurück zum Zitat Bockisch A, Freudenberg LS, Schmidt D, Kuwert T. Hybrid imaging by SPECT/CT and PET/CT: proven outcomes in cancer imaging. Semin Nucl Med 2009;39:276–89.CrossRefPubMed Bockisch A, Freudenberg LS, Schmidt D, Kuwert T. Hybrid imaging by SPECT/CT and PET/CT: proven outcomes in cancer imaging. Semin Nucl Med 2009;39:276–89.CrossRefPubMed
5.
Zurück zum Zitat Tharp K, Israel O, Hausmann J, Bettman L, Martin WH, Daitzchman M, et al. Impact of 131I-SPECT/CT images obtained with an integrated system in the follow-up of patients with thyroid carcinoma. Eur J Nucl Med Mol Imaging 2004;31:1435–42.CrossRefPubMed Tharp K, Israel O, Hausmann J, Bettman L, Martin WH, Daitzchman M, et al. Impact of 131I-SPECT/CT images obtained with an integrated system in the follow-up of patients with thyroid carcinoma. Eur J Nucl Med Mol Imaging 2004;31:1435–42.CrossRefPubMed
6.
Zurück zum Zitat Ruf J, Lehmkuhl L, Bertram H, Sandrock D, Amthauer H, Humplik B, et al. Impact of SPECT and integrated low-dose CT after radioiodine therapy on the management of patients with thyroid carcinoma. Nucl Med Commun 2004;25:1177–82.CrossRefPubMed Ruf J, Lehmkuhl L, Bertram H, Sandrock D, Amthauer H, Humplik B, et al. Impact of SPECT and integrated low-dose CT after radioiodine therapy on the management of patients with thyroid carcinoma. Nucl Med Commun 2004;25:1177–82.CrossRefPubMed
7.
Zurück zum Zitat Chen L, Luo Q, Shen Y, Yu Y, Yuan Z, Lu H, et al. Incremental value of 131I SPECT/CT in the management of patients with differentiated thyroid carcinoma. J Nucl Med 2008;49:1952–7.CrossRefPubMed Chen L, Luo Q, Shen Y, Yu Y, Yuan Z, Lu H, et al. Incremental value of 131I SPECT/CT in the management of patients with differentiated thyroid carcinoma. J Nucl Med 2008;49:1952–7.CrossRefPubMed
8.
Zurück zum Zitat Wong KK, Zarzhevsky N, Cahill JM, Frey KA, Avram AM. Incremental value of diagnostic 131I SPECT/CT fusion imaging in the evaluation of differentiated thyroid carcinoma. AJR Am J Roentgenol 2008;191:1785–94.CrossRefPubMed Wong KK, Zarzhevsky N, Cahill JM, Frey KA, Avram AM. Incremental value of diagnostic 131I SPECT/CT fusion imaging in the evaluation of differentiated thyroid carcinoma. AJR Am J Roentgenol 2008;191:1785–94.CrossRefPubMed
9.
Zurück zum Zitat Kohlfuerst S, Igerc I, Lobnig M, Gallowitsch HJ, Gomez-Segovia I, Matschnig S, et al. Posttherapeutic (131)I SPECT-CT offers high diagnostic accuracy when the findings on conventional planar imaging are inconclusive and allows a tailored patient treatment regimen. Eur J Nucl Med Mol Imaging 2009;36:886–93.CrossRefPubMed Kohlfuerst S, Igerc I, Lobnig M, Gallowitsch HJ, Gomez-Segovia I, Matschnig S, et al. Posttherapeutic (131)I SPECT-CT offers high diagnostic accuracy when the findings on conventional planar imaging are inconclusive and allows a tailored patient treatment regimen. Eur J Nucl Med Mol Imaging 2009;36:886–93.CrossRefPubMed
10.
Zurück zum Zitat Spanu A, Solinas ME, Chessa F, Sanna D, Nuvoli S, Madeddu G. 131I SPECT/CT in the follow-up of differentiated thyroid carcinoma: incremental value versus planar imaging. J Nucl Med 2009;50:184–90.CrossRefPubMed Spanu A, Solinas ME, Chessa F, Sanna D, Nuvoli S, Madeddu G. 131I SPECT/CT in the follow-up of differentiated thyroid carcinoma: incremental value versus planar imaging. J Nucl Med 2009;50:184–90.CrossRefPubMed
11.
Zurück zum Zitat Schmidt D, Szikszai A, Linke R, Bautz W, Kuwert T. Impact of 131I SPECT/spiral CT on nodal staging of differentiated thyroid carcinoma at the first radioablation. J Nucl Med 2009;50:18–23.CrossRefPubMed Schmidt D, Szikszai A, Linke R, Bautz W, Kuwert T. Impact of 131I SPECT/spiral CT on nodal staging of differentiated thyroid carcinoma at the first radioablation. J Nucl Med 2009;50:18–23.CrossRefPubMed
12.
Zurück zum Zitat Pacini F, Schlumberger M, Dralle H, Elisei R, Smit JWA, Wiersinga W, et al. European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur J Endocrinol 2006;154:787–803.CrossRefPubMed Pacini F, Schlumberger M, Dralle H, Elisei R, Smit JWA, Wiersinga W, et al. European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur J Endocrinol 2006;154:787–803.CrossRefPubMed
13.
Zurück zum Zitat Greene FL, Page DL, Fleming ID, Fritz A, Balch CM. AJCC cancer staging handbook. New York: Springer; 2002.CrossRef Greene FL, Page DL, Fleming ID, Fritz A, Balch CM. AJCC cancer staging handbook. New York: Springer; 2002.CrossRef
14.
Zurück zum Zitat Sawka AM, Thephamongkhol K, Brouwers M, Thabane L, Browman G, Gerstein HC. Clinical review 170: a systematic review and metaanalysis of the effectiveness of radioactive iodine remnant ablation for well-differentiated thyroid cancer. J Clin Endocrinol Metab 2004;89:3668–76.CrossRefPubMed Sawka AM, Thephamongkhol K, Brouwers M, Thabane L, Browman G, Gerstein HC. Clinical review 170: a systematic review and metaanalysis of the effectiveness of radioactive iodine remnant ablation for well-differentiated thyroid cancer. J Clin Endocrinol Metab 2004;89:3668–76.CrossRefPubMed
15.
Zurück zum Zitat Sawka AM, Brierley JD, Tsang RW, Thabane L, Rotstein L, Gafni A, et al. An updated systematic review and commentary examining the effectiveness of radioactive iodine remnant ablation in well-differentiated thyroid cancer. Endocrinol Metab Clin North Am 2008;37:457–80.CrossRefPubMed Sawka AM, Brierley JD, Tsang RW, Thabane L, Rotstein L, Gafni A, et al. An updated systematic review and commentary examining the effectiveness of radioactive iodine remnant ablation in well-differentiated thyroid cancer. Endocrinol Metab Clin North Am 2008;37:457–80.CrossRefPubMed
16.
Zurück zum Zitat Handkiewicz-Junak D, Wloch J, Roskosz J, Krajewska J, Kropinska A, Pomorski L, et al. Total thyroidectomy and adjuvant radioiodine treatment independently decrease locoregional recurrence risk in childhood and adolescent differentiated thyroid cancer. J Nucl Med 2007;48:879–88.CrossRefPubMed Handkiewicz-Junak D, Wloch J, Roskosz J, Krajewska J, Kropinska A, Pomorski L, et al. Total thyroidectomy and adjuvant radioiodine treatment independently decrease locoregional recurrence risk in childhood and adolescent differentiated thyroid cancer. J Nucl Med 2007;48:879–88.CrossRefPubMed
17.
Zurück zum Zitat Mazzaferri EL, Kloos RT. Clinical review 128: current approaches to primary therapy for papillary and follicular thyroid cancer. J Clin Endocrinol Metab 2001;86:1447–63.CrossRefPubMed Mazzaferri EL, Kloos RT. Clinical review 128: current approaches to primary therapy for papillary and follicular thyroid cancer. J Clin Endocrinol Metab 2001;86:1447–63.CrossRefPubMed
18.
Zurück zum Zitat Hay ID, McDougall IR, Sisson JC. A proposition for the use of radioiodine in WDTC management. J Nucl Med 2009;50:329–30.CrossRef Hay ID, McDougall IR, Sisson JC. A proposition for the use of radioiodine in WDTC management. J Nucl Med 2009;50:329–30.CrossRef
19.
Zurück zum Zitat Verburg FA, Dietlein M, Lassmann M, Luster M, Reiners C. Why radioiodine remnant ablation is right for most patients with differentiated thyroid carcinoma. Eur J Nucl Med Mol Imaging 2009;36:343–6.CrossRefPubMed Verburg FA, Dietlein M, Lassmann M, Luster M, Reiners C. Why radioiodine remnant ablation is right for most patients with differentiated thyroid carcinoma. Eur J Nucl Med Mol Imaging 2009;36:343–6.CrossRefPubMed
20.
Zurück zum Zitat Bonnet S, Hartl D, Leboulleux S, Baudin E, Lumbroso JD, Al Ghuzlan A, et al. Prophylactic lymph node dissection for papillary thyroid cancer less than 2 cm: implications for radioiodine treatment. J Clin Endocrinol Metab 2009;94:1162–7.CrossRefPubMed Bonnet S, Hartl D, Leboulleux S, Baudin E, Lumbroso JD, Al Ghuzlan A, et al. Prophylactic lymph node dissection for papillary thyroid cancer less than 2 cm: implications for radioiodine treatment. J Clin Endocrinol Metab 2009;94:1162–7.CrossRefPubMed
21.
Zurück zum Zitat Ali N, Sebastian C, Foley RR, Murray I, Canizales AL, Jenkins PJ, et al. The management of differentiated thyroid cancer using 123I for imaging to assess the need for 131I therapy. Nucl Med Commun 2006;27:165–9.CrossRefPubMed Ali N, Sebastian C, Foley RR, Murray I, Canizales AL, Jenkins PJ, et al. The management of differentiated thyroid cancer using 123I for imaging to assess the need for 131I therapy. Nucl Med Commun 2006;27:165–9.CrossRefPubMed
22.
Zurück zum Zitat Gemsenjäger E, Perren A, Seifert B, Schüler G, Schweizer I, Heitz PU. Lymph node surgery in papillary thyroid carcinoma. J Am Coll Surg 2003;197:182–90.CrossRefPubMed Gemsenjäger E, Perren A, Seifert B, Schüler G, Schweizer I, Heitz PU. Lymph node surgery in papillary thyroid carcinoma. J Am Coll Surg 2003;197:182–90.CrossRefPubMed
23.
Zurück zum Zitat Shindo M, Wu JC, Park EE, Tanzella F. The importance of central compartment elective lymph node excision in the staging and treatment of papillary thyroid cancer. Arch Otolaryngol Head Neck Surg 2006;132:650–4.CrossRefPubMed Shindo M, Wu JC, Park EE, Tanzella F. The importance of central compartment elective lymph node excision in the staging and treatment of papillary thyroid cancer. Arch Otolaryngol Head Neck Surg 2006;132:650–4.CrossRefPubMed
24.
Zurück zum Zitat Machens A, Holzhausen HJ, Dralle H. Skip metastases in thyroid cancer leaping the central lymph node compartment. Arch Surg 2004;139:43–5.CrossRefPubMed Machens A, Holzhausen HJ, Dralle H. Skip metastases in thyroid cancer leaping the central lymph node compartment. Arch Surg 2004;139:43–5.CrossRefPubMed
25.
Zurück zum Zitat Durante C, Haddy N, Baudin E, Leboulleux S, Hartl D, Travagli JP, et al. Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy. J Clin Endocrinol Metab 2006;91:2892–9.CrossRefPubMed Durante C, Haddy N, Baudin E, Leboulleux S, Hartl D, Travagli JP, et al. Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy. J Clin Endocrinol Metab 2006;91:2892–9.CrossRefPubMed
26.
Zurück zum Zitat Zanotti-Fregonara P, Grassetto G, Hindié E, Rubello D. A low thyroglobulin level cannot be used to avoid adjuvant 131I therapy after thyroidectomy for thyroid carcinoma. Eur J Nucl Med Mol Imaging 2009;36:169–71.CrossRefPubMed Zanotti-Fregonara P, Grassetto G, Hindié E, Rubello D. A low thyroglobulin level cannot be used to avoid adjuvant 131I therapy after thyroidectomy for thyroid carcinoma. Eur J Nucl Med Mol Imaging 2009;36:169–71.CrossRefPubMed
Metadaten
Titel
Five months’ follow-up of patients with and without iodine-positive lymph node metastases of thyroid carcinoma as disclosed by 131I-SPECT/CT at the first radioablation
verfasst von
Daniela Schmidt
Rainer Linke
Michael Uder
Torsten Kuwert
Publikationsdatum
01.04.2010
Verlag
Springer-Verlag
Erschienen in
European Journal of Nuclear Medicine and Molecular Imaging / Ausgabe 4/2010
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089
DOI
https://doi.org/10.1007/s00259-009-1299-2

Weitere Artikel der Ausgabe 4/2010

European Journal of Nuclear Medicine and Molecular Imaging 4/2010 Zur Ausgabe